Sarcoptic mite isotropic agent and device for preventing and treating sarcoptic mites and application of sarcoptic mite isotropic agent

By using β-mites lactone to interfere with the chemical communication of scabies mites and combining sustained release materials to prepare scabies mites mites, the problem of drug resistance and short-lived efficacy of scabies mites in the prior art is solved, and effective scabies mites are achieved Disease prevention and treatment and long-term effects.

CN118975561APending Publication Date: 2024-11-19NORTHWEST A & F UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411052518.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The drugs used in the prior art to prevent and control scabies mites are prone to cause mite resistance, and the effect time is short, making it difficult to effectively solve the problem of repeated infection of scabies mites.

Method used

Use β-mitesolactone as sex pheromone agent to interfere with the chemical communication between male and female, reduce the mating rate, reduce the number of offspring, and prepare a scabies mite agent and device by combining it with sustained release materials. , used for the prevention and control of pig scabies mite disease.

Benefits of technology

It effectively improves the symptoms of pig scabies mite disease, reduces the incidence rate, and prolongs the effectiveness period, solves the problem of repeated infection of scabies mites, and is environmentally friendly and has innovative significance in animal ectopic parasitic disease prevention and control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118975561A_ABST
    Figure CN118975561A_ABST
Patent Text Reader

Abstract

The invention provides a sarcoptic mite isotropic agent and device for preventing and treating sarcoptic mites and application, and belongs to the technical field of biological prevention and treatment of pests. The invention provides an application of beta-acarinolide in prevention and treatment of sarcoptic mites. The invention relates to a sex pheromone isotropic agent which is mainly composed of beta-acarinolide. Wherein the beta-acarinolide interferes and even blocks chemical communication between male and female insects and puts the male insects into confusion, so that the male and female insects cannot normally mate, the mating rate is reduced, the number of offspring is reduced, and biological prevention and treatment are carried out on the swine sarcoptic acariasis. The beta-acarlactone can effectively improve related symptoms of swine sarcoptic acariasis and reduce the morbidity, is long in lasting period and environment-friendly, and can efficiently solve the problem of repeated infection of sarcoptic mites. According to the invention, the sex pheromone isotropic technology is applied to prevention and treatment of animal ectoparasitic diseases for the first time, and the application has important significance for innovative preparation research and development.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biological pest control, and in particular relates to a scabies disorienting agent for controlling scabies, a device and an application thereof. Background Art

[0002] Swine scabies is one of the parasitic diseases that seriously harm the pig farming industry. In recent years, with the emphasis on deworming of pigs and the optimization of the breeding environment, large-scale outbreaks of internal parasites have become less and less common. Instead, the incidence of surface parasitic diseases represented by scabies is higher. The disease is a chronic, contact, and contagious skin disease caused by scabies mites that parasitize the skin of pigs. The disease is relatively widespread in autumn, winter, and early spring, but after spring, scabies mites are only in a hidden state, hiding in the wrinkles of the skin of sick pigs and places where sunlight is insufficient, hiding until autumn and recurring again. Scabies does not distinguish between age and breed. Pigs of all breeds and ages can be infected and fall ill. Pigs under 5 months old are most susceptible and have the most severe symptoms. The main characteristics are severe itching, hair loss, scabs, thickened and wrinkled skin or cracks, and progressive weight loss. In severe cases, it will lead to slow growth and development of piglets, reduced semen quality of boars, and even affect estrus and lactation of sows, seriously endangering the production performance of pigs. Scabies mites are small in size, about 0.2-0.5 mm, parasitizing in the deep layer of pig skin, living in tunnels dug by the worm body, and mainly relying on exuded lymph and skin stratum corneum tissue for survival. They develop and reproduce in the tunnels. Female mites lay eggs in the tunnels, 1-2 eggs per day, and can lay about 40-50 eggs in their lifetime. After ovulation, the female mites die. The development process is divided into 4 stages, including eggs, larvae, nymphs, and adults. The eggs hatch into larvae after 3-7 days. The larvae leave the tunnels of the mother mites and drill into the skin through the hair follicles again, forming a small tunnel. After 3-5 days, the larvae enter a dormant state and shed their skin to become nymphs with 4 pairs of legs. The nymphs burrow into new tunnels and become adults after 5 to 7 days and secondary molting. The entire development process takes an average of about 15 days. Scabies mites have strong reproductive capacity and a wide range of transmission routes. They can be transmitted through contact, or they can be infected by contact with sick pig excrement or contaminated feeding tools.

[0003] Avermectin or ivermectin is currently the main drug used to prevent and treat scabies. Common veterinary clinical dosage forms include tablets, injections, pour-ons, etc. However, long-term and repeated use of such drugs can easily lead to drug resistance in mites, resulting in repeated infection of scabies mites, and the drug has a short duration of effectiveness. Summary of the invention

[0004] In view of the defects in the prior art, the purpose of the present invention is to provide an application of β-acarinolide in the prevention and treatment of scabies, which can effectively solve the problem of repeated infection of scabies and has a long lasting effect.

[0005] The objective of the present invention is achieved through the following technical solutions:

[0006] The invention provides application of beta-mitrolactone in preventing and controlling scabies.

[0007] The invention provides a scabies disorienting agent for preventing and treating scabies, comprising beta-carinolide.

[0008] Preferably, the scabies disorienting agent further comprises an organic component;

[0009] The scabies disorienting agent comprises, by weight, 5 to 15 parts of beta-mitrolactone and 0.5 to 13 parts of organic components.

[0010] Preferably, the organic component includes: any one or more of 2,6-dichlorophenol, methyl salicylate and 2-nitrophenol.

[0011] The invention provides a device for preventing and treating scabies, the device comprising the scabies disorienting agent and a slow-release material according to the above technical solution; the slow-release material comprises a capillary; the capillary comprises any one or more of a polyvinyl chloride capillary, a polyethylene capillary, a butyl rubber capillary, a natural rubber capillary, a polyvinyl alcohol capillary and an ethylene-acetate-ethylene copolymer capillary.

[0012] Preferably, the scabies averting agent is loaded in a sustained-release material.

[0013] Preferably, the loading amount of the scabies disorienting agent in each of the sustained-release materials is 200-400 mg.

[0014] The invention provides a preparation for preventing and treating scabies, comprising the scabies disorienting agent or the device described in the above technical solution; the preparation also comprises other drugs for preventing and treating mites; the other drugs for preventing and treating mites include an ivermectin pour-on.

[0015] The present invention provides the use of the scabies disorienting agent described in the above technical solution, the device described in the above technical solution or the preparation described in the above technical solution in preventing and controlling scabies.

[0016] The present invention also provides a method for preventing and controlling scabies, comprising: in a space to be prevented and controlled, every 10 to 20 m 3 A device described in the above technical solution is placed in the space.

[0017] Beneficial effects of the present invention:

[0018] The present invention provides the use of β-acaridone (2(E)-(4-methyl-3-pentenylidene)butanedial, β-Acaridial, 2(E)-(4-methyl-3-pentenylidene)butanedial) in the prevention and treatment of scabies. The present invention utilizes β-acaridone, the main component of the sex pheromone disorienting agent, wherein β-acaridone confuses male insects by interfering with or even blocking the chemical communication between males and females, making it impossible for the male and female insects to mate normally, thereby reducing their mating rate and the number of their offspring, thereby biologically controlling swine scabies. The β-acaridone of the present invention can effectively improve the relevant symptoms of swine scabies and reduce the incidence rate. At the same time, it has a long lasting effect, is environmentally friendly, and can effectively solve the problem of repeated infection of scabies. The present invention is the first to apply the sex pheromone disorienting technology to the prevention and treatment of animal ectoparasitic diseases, which is of great significance for the research and development of innovative preparations. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.

[0020] Figure 1 This is a schematic diagram of the ivermectin pour-on solution product used in Application Example 1;

[0021] Figure 2 A physical picture of the device for preventing and controlling scabies prepared in Example 2;

[0022] Figure 3 This is a graph showing the skin symptom scoring results of each test group at different times in Application Example 1;

[0023] Figure 4 This is a graph showing the monitoring results of the number of mites on pig skin in each test group of Application Example 1. DETAILED DESCRIPTION

[0024] The invention provides application of beta-mitrolactone in preventing and controlling scabies.

[0025] The present invention utilizes β-acaridone, the main component of the sex pheromone averting agent; the chemical formula name of the β-acaridone is: 2(E)-(4-methyl-3-pentenyl)-succinaldehyde, and the English name is: β-Acaridial, 2(E)-(4-methyl-3-pentenylidene)butanedial. β-acaridone confuses male insects by interfering or even blocking the chemical communication between males and females, making it impossible for male and female insects to mate normally, thereby reducing their mating rate and the number of their offspring, and then biologically controlling scabies mites and improving the symptoms of scabies caused by scabies mites. In the present invention, the scabies mites preferably include swine scabies. The β-acaridone of the present invention can effectively improve the relevant symptoms of swine scabies and reduce the incidence rate. At the same time, it has a long lasting effect, is environmentally friendly, and can effectively solve the problem of repeated infection of scabies mites. The present invention is the first to apply the sex pheromone averting technology to the prevention and treatment of animal ectoparasitic diseases, which is of great significance for the development of innovative preparations.

[0026] The present invention provides a scabies disorienting agent for preventing and controlling scabies, comprising β-carinolide. In the present invention, the scabies disorienting agent preferably further comprises an organic component.

[0027] Unless otherwise specified, the present invention has no particular limitation on the sources of the raw materials, and any conventional source in the art may be used.

[0028] In the present invention, if the scabies disorienting agent includes an organic component, the scabies disorienting agent preferably includes 5 to 15 parts of β-carid lactone, more preferably 10 to 15 parts, and more preferably 15 parts by weight. In the present invention, the source of the β-carid lactone is preferably laboratory synthesis. The present invention has no special restrictions on the synthesis method of the β-carid lactone, and any conventional synthesis method in the art can be used. The synthesis method of β-carid lactone in the embodiment of the present invention is detailed in the reference (Nobuhiro Shimizu, Naoki Mori and Yasumasa Kuwahara, Simple Synthesis of Mite Pheromonebeta-Acaridial and Its Analogs in the Secretion of Caloglyphus polyphyllae (Acari: Acaridae), Biosci. Biotech Biochem., 67 (8), 1732-1736, 2003).

[0029] Based on the mass percentage of β-carinolide, the scabies disorienting agent provided by the present invention preferably includes 0.5 to 13 parts of organic components. In the present invention, the organic components preferably include any one or more of 2,6-dichlorophenol, methyl salicylate and 2-nitrophenol, and more preferably include 2,6-dichlorophenol, methyl salicylate and 2-nitrophenol.

[0030] In the present invention, if the organic component includes 2,6-dichlorophenol, based on the mass of β-acarin, the added amount of 2,6-dichlorophenol is preferably 1 to 4 parts, more preferably 2 to 4 parts, and more preferably 3.5 parts.

[0031] In the present invention, if the organic component includes methyl salicylate, based on the mass fraction of β-acarinol, the added amount of methyl salicylate is preferably 0.5 to 5 parts, more preferably 2 to 5 parts, and even more preferably 4 parts.

[0032] In the present invention, if the organic component includes 2-nitrophenol, the added amount of 2-nitrophenol is preferably 1 to 4 parts, more preferably 1 to 3 parts, and even more preferably 2 parts, based on the mass of β-acarin.

[0033] In the present invention, the organic component helps the stable volatilization of β-mitrolactone, and can also increase the aggregation attraction of scabies mites, and synergistically exert the effect of preventing and controlling scabies mites with β-mitrolactone.

[0034] The present invention provides a device for preventing and treating scabies, the device comprising the scabies disorienting agent and a sustained-release material according to the above technical solution; the sustained-release material comprises a capillary; the capillary comprises any one or more of a polyvinyl chloride capillary, a polyethylene capillary, a butyl rubber capillary, a natural rubber capillary, a polyvinyl alcohol capillary and an ethylene-acetate-ethylene copolymer capillary. In the present invention, the device preferably loads the scabies disorienting agent in the sustained-release material; the length of the sustained-release material is preferably 10 to 20 cm, more preferably 20 cm; the inner diameter of the sustained-release material is preferably 1 to 2 mm, more preferably 1.5 mm. In the present invention, the loading amount of the scabies disorienting agent in the sustained-release material is preferably 200 to 400 mg, more preferably 200 mg.

[0035] The present invention also provides a preparation for preventing and treating scabies, comprising the scabies disorienting agent described in the above technical solution or the device described in the above technical solution; the preparation also comprises other drugs for preventing and treating scabies; the other drugs for preventing and treating scabies include ivermectin pour-on. In the present invention, the preparation combines the scabies disorienting agent with the ivermectin pour-on for the prevention and treatment of swine scabies. The combined use of the scabies disorienting agent and the ivermectin pour-on can significantly alleviate the clinical symptoms of scabies-infected bodies compared to the use of the scabies disorienting agent or the ivermectin pour-on alone, and also significantly reduces the number of scabies in the skin tissue of the scabies-infected body, and greatly inhibits the recurrence of scabies. In the present invention, when the preparation is in use, the device can be directly placed in the space where scabies are to be prevented and treated; the device is preferably placed every 10 to 20 m 3 The preparation provided by the present invention, which is used in combination with other mite control drugs such as ivermectin pour-on agent, can achieve a synergistic technical effect in the prevention and treatment of scabies in scabies infected bodies.

[0036] The present invention provides the use of the scabies disorienting agent, the device or the preparation described in the above technical solution in the prevention and treatment of scabies. In the present invention, the scabies preferably include swine scabies. The scabies disorienting agent, the device or the preparation provided by the present invention can effectively improve the relevant symptoms of swine scabies, reduce the number of scabies, and reduce the incidence rate. At the same time, the effect is long-lasting, environmentally friendly, and can effectively solve the problem of repeated infection of scabies.

[0037] The present invention also provides a method for preventing and controlling scabies, comprising: in a space for preventing and controlling scabies, every 10 to 20 m 3 The device of the present invention is preferably placed in a space of 10 to 20 m2 in the livestock and poultry feeding space. 3 Place one, preferably every 10m 3 In the present invention, if the device is used in combination with other drugs for preventing and treating mites, the present invention has no special limitation on the method of using other drugs for preventing and treating mites, and conventional methods of use may be used.

[0038] In order to further illustrate the present invention, the technical solution provided by the present invention is described in detail below in conjunction with the accompanying drawings and embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0039] Example 1

[0040] A scabies disorienting agent for preventing and treating scabies, comprising, by weight:

[0041] 8 parts of β-carbene lactone, 3 parts of 2,6-dichlorophenol, 3 parts of methyl salicylate and 2 parts of 2-nitrophenol.

[0042] The preparation method of the scabies disorienting agent is:

[0043] After β-carinolide, 2,6-dichlorophenol, methyl salicylate and 2-nitrophenol are uniformly mixed according to the above mass parts, a scabies disorienting agent for preventing and controlling scabies is obtained.

[0044] Example 2

[0045] A device for preventing and treating scabies, specifically: the scabies disorienting agent prepared in Example 1 is loaded into a polyvinyl chloride capillary tube with a slow-release effect, the capillary tube is 20 cm long and has an inner diameter of 1.5 mm. The loading amount of each capillary tube is 200 mg. The actual picture of the prepared device for preventing and treating scabies is as follows Figure 2 shown.

[0046] Example 3

[0047] A scabies disorienting agent for preventing and treating scabies, comprising, by weight:

[0048] 5 parts of β-acarinol, 1 part of 2,6-dichlorophenol, 0.5 parts of methyl salicylate and 1 part of 2-nitrophenol.

[0049] The preparation method of the scabies disorienting agent is the same as that in Example 1.

[0050] Example 4

[0051] A device for preventing and treating scabies, specifically: the scabies disorienting agent prepared in Example 3 for preventing and treating scabies is loaded into a butyl rubber capillary with a slow-release effect, the capillary is 20 cm long and has an inner diameter of 1.5 mm, and the loading amount of each capillary is 200 mg.

[0052] Example 5

[0053] A scabies disorienting agent for preventing and treating scabies, comprising, by weight:

[0054] 15 parts of β-carbene lactone, 4 parts of 2,6-dichlorophenol, 5 parts of methyl salicylate and 4 parts of 2-nitrophenol.

[0055] The preparation method of the scabies disorienting agent is the same as that in Example 1.

[0056] Example 6

[0057] A device for preventing and treating scabies, specifically: the scabies disorienting agent prepared in Example 5 for preventing and treating scabies is loaded into a polyethylene capillary with a slow-release effect, the capillary is 20 cm long and has an inner diameter of 1.5 mm, and the loading amount of each capillary is 200 mg.

[0058] Example 7

[0059] A scabies disorienting agent for preventing and treating scabies, comprising, by weight:

[0060] 10 parts of β-carbene lactone, 3 parts of 2,6-dichlorophenol, 3 parts of methyl salicylate and 3 parts of 2-nitrophenol.

[0061] The preparation method of the scabies disorienting agent is the same as that in Example 1.

[0062] Example 8

[0063] A device for preventing and treating scabies, specifically: the scabies disorienting agent prepared in Example 7 for preventing and treating scabies is loaded into a natural rubber capillary with a slow-release effect, the capillary is 20 cm long and has an inner diameter of 1.5 mm, and the loading amount of each capillary is 200 mg.

[0064] Example 9

[0065] A scabies disorienting agent for preventing and treating scabies, comprising, by weight:

[0066] 10 parts of β-carbapenem lactone and 3 parts of 2,6-dichlorophenol.

[0067] The preparation method of the scabies disorienting agent is the same as that in Example 1.

[0068] Example 10

[0069] A device for preventing and treating scabies, specifically: the scabies disorienting agent prepared in Example 9 for preventing and treating scabies is loaded into a natural rubber capillary with a slow-release effect, the capillary is 20 cm long and has an inner diameter of 1.5 mm, and the loading amount of each capillary is 200 mg.

[0070] Embodiment 11

[0071] A scabies disorienting agent for preventing and treating scabies, comprising, by weight:

[0072] 10 parts of β-carbenicillin and 3 parts of methyl salicylate.

[0073] The preparation method of the scabies disorienting agent is the same as that in Example 1.

[0074] Example 12

[0075] A device for preventing and treating scabies, specifically: the scabies disorienting agent prepared in Example 11 for preventing and treating scabies is loaded into a natural rubber capillary with a slow-release effect, the capillary is 20 cm long and has an inner diameter of 1.5 mm, and the loading amount of each capillary is 200 mg.

[0076] Embodiment 13

[0077] A scabies disorienting agent for preventing and treating scabies, comprising, by weight:

[0078] 10 parts of β-acarin and 2 parts of 2-nitrophenol.

[0079] The preparation method of the scabies disorienting agent is the same as that in Example 1.

[0080] Embodiment 14

[0081] A device for preventing and treating scabies, specifically: the scabies disorienting agent prepared in Example 13 for preventing and treating scabies is loaded into a natural rubber capillary with a slow-release effect, the capillary is 20 cm long and has an inner diameter of 1.5 mm, and the loading amount of each capillary is 200 mg.

[0082] Embodiment 15

[0083] A substance for controlling scabies consisting solely of beta-acarinol.

[0084] The device for preventing and controlling scabies mites is to load β-carinolide into a polyvinyl chloride capillary tube with a slow-release effect, the capillary tube is 20 cm long and has an inner diameter of 1.5 mm, and the loading amount of each capillary tube is 200 mg.

[0085] Application Example 1

[0086] The effect of the scabies aversion agent for controlling scabies in Example 1 was monitored in a pig farm where scabies occurred.

[0087] 1. Select 20 healthy pigs without scabies infection, randomly divide them into four groups, and keep them in separate pens far away from each other. Adaptive feeding is carried out for 5 to 7 days before the start of the experiment. After the start of the experiment, the pigs in each test group are infected with the same amount of scabies.

[0088] On the 21st day after infection, each experimental group was treated as follows: the first group was used as the scabies control group and no treatment was given; the second group was treated with ivermectin pour-on solution, which was recorded as the IVM pour-on solution treatment group (IVM pour-on solution, commercially available IVM pour-on solution, purchased from Inner Mongolia Jinhe Animal Pharmaceutical Co., Ltd., detailed information of the pour-on solution is as follows: Figure 1 As shown, the specific method of using the pour-on agent is: pouring along the head and spine to allow the liquid to flow slowly) for treatment; the third group was treated with ivermectin pour-on agent (the source and dosage of the pour-on agent were the same as above), and the scabies pheromone disorienting agent release device prepared in Example 2 was placed in the pen, recorded as: IVM pour-on agent + disorienting agent (the release device depends on the size of the pen, an average of every 10m 3 The fourth group did not use ivermectin pouring agent, and only placed the scabies pheromone disorienting agent release device prepared in Example 2 in the pen, which was recorded as: the disorienting agent treatment group (the release device depends on the size of the pen, an average of 10m 3 Place one).

[0089] 2. After the start of the experiment, the scabies lesions (0 to 6), skin erythema (0 to 4) and scabs (0 to 4) of different anatomical parts of each group of pigs were scored on day 0 (i.e. the day when the pigs were infected with equal amounts of scabies), day 3, day 6, day 9, day 12, day 15, day 18, day 21, day 24, day 27, day 30, day 33, day 36, day 39, day 42 and day 45 (the scoring criteria can be found in the literature "Study on the sensitivity of scabies to new drugs and analysis of genetic diversity"), and the course of skin lesions in each group of pigs was recorded. The results are shown in Tables 1 and Figure 3 .

[0090] Table 1 Skin symptom scores of each test group at different times

[0091]

[0092] From Table 1 and Figure 3 It can be analyzed that the test results show that compared with the control group, the ivermectin pour-on treatment group can significantly improve the dermatitis symptoms of pigs, and the wounds such as scabies and erythema are reduced, but the scabies symptoms of pigs began to recur after 33 days, and the condition tended to be serious; in the ivermectin and azithromycin combined treatment group, the scabies dermatitis symptoms of pigs were also significantly alleviated, but there was no recurrence; the treatment effect of the azithromycin treatment group was relatively slower than that of the combined treatment group, but the dermatitis symptoms of scabies in pigs have been tending to be alleviated, and there was no recurrence within 45 days.

[0093] 3. After the start of the experiment, skin tissues from five different anatomical parts of each group of pigs were scraped on days 0, 12, 21, 27, 30, 33, 39 and 45, and the number of mites was counted under a microscope and analyzed for differences. The results are shown in Tables 2 and Figure 4 .

[0094] Table 2 Monitoring of the number of mites on pig skin in each test group

[0095]

[0096] From Table 2 and Figure 4 The experimental results showed that compared with the control group, the ivermectin pour-on treatment group could significantly reduce the number of scabies mites in the skin tissue of pigs, but the number of scabies mites in pigs began to increase again after 33 days; in the ivermectin and azithromycin combined treatment group, the number of scabies mites in pigs was significantly reduced, but there was no recurrence; the treatment effect of the azithromycin treatment group was compared with the combined treatment group, the trend of reducing the number of scabies mites was slower, and there was no recurrence within 45 days.

[0097] Application Example 2

[0098] Forty-five healthy pigs without scabies infection were selected and randomly divided into 9 groups. They were kept in independent pens far away from each other. They were adaptively fed for 5 to 7 days before the start of the experiment. After the start of the experiment, the pigs in each test group were infected with the same amount of scabies.

[0099] On the 21st day after infection, each test group was treated in the following manner: one group was used as the scabies control group and was not given any treatment measures; the other test groups were placed in the pens with the scabies pheromone disorienting agent release devices prepared in Examples 2, 4, 6, 8, 10, 12, 14 and 15, respectively. The release device was determined according to the size of the pen, with an average of 10 m 3 Place one.

[0100] After the start of the experiment, skin tissues from five different anatomical parts of the pigs in each group were scraped on day 45, the number of mites was counted under a microscope, and a differential analysis was performed. The results are shown in Table 3.

[0101] Table 3 Monitoring of the number of mites on pig skin in each test group

[0102] Group Number of mites (mean±SD) Example 2 35±2.8 Example 4 45±1.8 Example 6 29±3.3 Example 8 32±2.7 Example 10 30±2.1 Example 12 31±1.9 Embodiment 14 30±3.2 Embodiment 15 26±3.7 Control group 100±6.7

[0103] It can be seen from Table 3 that the scabies pheromone averting agent prepared by the present invention can play a good effect in preventing and controlling scabies mites, and the effect is better when the proportion of β-mitrolactone in the averting agent releasing device is more than ten parts.

[0104] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. Application of β-carinolide in the prevention and treatment of scabies.

2. A scabies disorienting agent for preventing and treating scabies, characterized in that: Including beta-carotene.

3. The scabies disorienting agent according to claim 2, characterized in that: The scabies disorienting agent also includes an organic component; The scabies disorienting agent comprises, by weight, 5 to 15 parts of beta-mitrolactone and 0.5 to 13 parts of organic components.

4. The scabies disorienting agent according to claim 3, characterized in that: The organic components include: any one or more of 2,6-dichlorophenol, methyl salicylate and 2-nitrophenol.

5. A device for preventing and treating scabies, characterized in that: The device comprises the scabies disorienting agent according to any one of claims 2 to 4 and a sustained-release material; the sustained-release material comprises a capillary; the capillary comprises any one or more of polyvinyl chloride capillaries, polyethylene capillaries, butyl rubber capillaries, natural rubber capillaries, polyvinyl alcohol capillaries and ethylene-acetate-ethylene copolymer capillaries.

6. The device according to claim 5, characterized in that: The scabies averting agent is loaded in a sustained-release material.

7. The device according to claim 6, characterized in that: The loading amount of the scabies disorienting agent in each of the sustained-release materials is 200-400 mg.

8. A preparation for preventing and treating scabies, characterized in that: The invention comprises the scabies disorienting agent as claimed in any one of claims 2 to 4 or the device as claimed in any one of claims 5 to 7; the preparation also comprises other drugs for preventing and treating mites; the other drugs for preventing and treating mites comprise ivermectin pour-on.

9. Use of the scabies disorienting agent according to any one of claims 2 to 4, the device according to any one of claims 5 to 7 or the preparation according to claim 8 in preventing and controlling scabies.

10. A method for preventing and treating scabies, characterized in that: include: In the space to be controlled for scabies, every 10 to 20 m 3 A device according to any one of claims 5 to 7 is placed in the space.